SUMMARY
INTRODUCTION
Hepatitis E (HEV) was initially identified in the late 1970s as an epidemic non-A non-B hepatitis that caused an infectious waterborne illness similar to hepatitis A 1 . Now, HEV is a leading cause of icteric hepatitis and acute liver failure in the developing world. Worldwide, the estimated annual incidence of HEV infection is 20 million, resulting in around 56,600 deaths HEV infection in Western countries, mainly associated with genotype 3 4, 5 . Worldwide endemicity for HEV (all genotypes) is detailed in Figure 1 6
. Furthermore, chronic HEV infection has been recognised since 2008 7 , and in transplant recipients this may lead to cirrhosis and organ failure 8 .
In this review we detail current understanding of the molecular biology of HEV, clinical relevance of genotypic HEV infection, diagnostic and therapeutic strategies and propose future directions for basic science and clinical research.
METHODS
A systematic search was performed using the PubMed electronic database for relevant English language abstracts and full text articles published between 1990 and January 2017. Manual review of the reference lists of selected full text articles was also undertaken to identify additional eligible articles. The search terms included: 'hepatitis E', 'viral hepatitis', 'autochthonous infection', 'antiviral therapy', 'liver transplantation', 'acute', 'chronic', 'HEV', 'genotype', 'transmission' 'food borne', 'transfusion' and 'ribavirin'.
THE MOLECULAR BIOLOGY OF HEPATITIS E VIRUS
HEV is a small (27-34mm) single-stranded RNA virus 9 , approximately 7.2kb in length with 7 currently recognised genotypes 10 . It is known to be non-enveloped in bile and faeces, and is present in blood, coated in a lipid membrane. HEV consists of a 5' short non-coding region (NCR), ORF1 (which encodes the non-structural proteins), ORF3 (which encodes a small multifunctional protein), ORF2
(which encodes the capsid protein) and a 3'NCR followed by a polyadenosine tail approximately 150-
bases long (Figure 2). A novel fourth open reading frame (ORF4) has been identified, situated
within the ORF1 region of the HEV genome, encoding a 20kDa (139-158aa long) protein during endoplasmic reticulum stress which interacts with host and viral proteins to control the activity of the viral RNA dependent RNA polymerase 11 . However, ORF4 is unique to, although universal amongst, genotype 1 HEV strains.
ORF1 and ORF2/3 are separated by a junction region (JR), whereas ORF2 and ORF3 overlap and are transcribed as a bicistronic subgenomic mRNA 12 . The genome contains 2 cis-reactive elements (CREs), one in the JR and one overlapping the 3' end of ORF2 and the 3'NCR 13, 14 . The sequence and stem loop structure of the CRE in the JR is essential for replication and may also serve as the promoter for the subgenomic region 12 . The 3'NCR CRE localises the RNA-dependent RNA polymerase 15 . The 5' end of both the genomic and subgenomic RNA is capped 16 . A 76 nucleotide region in the 5'NCR is responsible for binding the ORF2 protein and is considered to play a role in viral assembly 17 . The coding region of ORF1 begins immediately after the 5'NCR and extends over . However, the protease activity of the PCP domain is a subject of some debate, with some reports suggesting that this domain may instead de-ubiquinate proteins, preventing the prosomal degradation of protein required for viral replication 19 . The capsid protein of HEV is expressed by ORF2. The ORF2 protein contains 4 domains; the N terminals, arginine rich, shell, middle and protruding domain. Neutralizing antibodies have been shown to bind to the P and M domains, suggesting that these play a role in cell binding and entry 20 . Studies involving the expression of a truncated form of ORF2 by a baculovirus expression system in insect cells have produced HEV like particles 21 . Such virus like particles have been shown to bind to heparan sulfate proteoglycans (HSPGs) and HSPG expression on the cell surface is required for in vitro infection 22 . ORF3 encodes a small 114 amino acid protein approximately 13kDa in size. The ORF3 protein is believed to interact with several cell proteins to facilitate HEV replication, for example; interacts with hemopexin (affecting iron homeostasis), binds to SH3 domain containing proteins (which function in the signal transduction pathway and promote cell survival) and interacts with Tsg101 and α1-microglobulin to facilitate the sorting of the endosomal sorting complexes required for transport (ESCRT) 23, 24, 25) . However, ORF3
protein's key role is believed to be in viral assembly and egress, with phosphorylated ORF3
interacting with the capsid protein 26 . Interestingly monoclonal antibodies to ORF3 were able to bind nascent virions but not faecal virions 27 . Further studies indicated that virions circulating in human serum banded at a lower sucrose gradient in comparison to faecally derived virions and were not neutralized by the presence of antibodies in cell culture systems in the way faecally derived virions were suggesting that virions circulating in sera are protected by a membrane, containing, at least in part, ORF3 28 .
Negative sense intermediate replicates are detected during replication and attachment receptors have been identified but overall, the viral life cycle of HEV has not been extensively studied 29, 30 . This is, in part, due to the slow progress in the development of reliable culture methods for HEV. Similarly, in vivo studies have been hampered due to the absence of a small animal model, until recently; with three studies achieving viral inoculation of human liver chimeric mice with HEV 31, 32, 33 . Interestingly, these reports indicated greater success using genotype 1 strains as inoculants (in contrast to in vitro studies) and all achieved greater infection and viraemia rates in inoculated mice using faecally derived HEV virions, in comparison to serum or culture derived. Two studies examined the use of ribavirin in inoculated chimeric mice and demonstrated the treatment to be successful in reducing viraemia in therapeutics 31, 33 . However, ribavirin induced anaemia was common in the treated mice (a side effect documented in humans) 31 .
HEV Phylogeny
All HEV strains belong to the family Hepeviridae, which has not been assigned to any order. The . HEV appears to be unique amongst human hepatitis viruses, as recombination events appear to alter the replicative capacity, tissue specificity and pathogenicity of HEV 37 .
Genotypes 1 and 2
Genotypes 1 and 2 are endemic in developing countries, where they cause water-borne outbreaks.
These are obligate human pathogens, transmitted via the faeco-oral route and clinical presentation with genotype 1 or 2 infection is indistinguishable from any other cause of acute viral hepatitis.
Genotypes 3 and 4
The most common mode of HEV transmission in developed countries is believed to be food-borne zoonosis 38 . Evidence of HEV as a zoonosis first came from the detection of HEV in pigs with a high homology to HEV strains found in humans 39 . Since then many potential animal reservoirs for HEV have been identified 40 . Only genotypes 3 and 4 of the species orthohepevirus A, and genotype 7, are recognised as zoonotic and circulate mainly in developed countries 40 . Host species for genotypes 3 and 4 include pigs, deer, rabbits, mongoose, cattle, sheep and horses (39, 41. 42; 43; 44; 45) . Food-borne zoonosis of HEV has been documented in several case reports, and undercooked or raw pork has now been identified as a significant risk factor for human HEV infection. Transmission via contaminated shellfish 46 and soft fruits 47 is also recognised as a potential source of food-borne transmission.
Transmission via blood transfusion and transplantation has also been well documented.
Genotype 7
To . This suggests an inadequate trigger for the innate immune response contributes to the development and severity of HEV-induced acute liver failure in pregnancy.
Pregnancy is associated with a high level of steroid hormones, which may promote viral replication and suppress CD4 cells 55 . HEV-infected women with acute liver failure have lower CD4 counts and higher CD8 counts. Pregnant women with HEV acute liver failure have also been shown to have higher levels of oestrogen, progesterone and B-HCG compared with HEV negative patients or control healthy pregnant women 55 . The role of herbal medicines has also been debated, with one group suggesting that HEV-infected pregnant women may be more likely to take herbal medicines, which could also contribute to the high mortality in certain geographical regions 56 .
In addition, in Central Asia and eastern Africa, high mortality rates have also been reported amongst HEV infected children aged under 2 years 57, 58 .
Clinical Features
The majority of acute HEV infections are asymptomatic; if present (in 20% of those with genotype 1 or 2 HEV infection) 3 , symptoms are often non-specific and include anorexia, nausea, fatigue, myalgia and jaundice. Laboratory tests show elevated serum bilirubin levels and a marked rise in liver enzymes. The mean incubation period is 40 days (range 15-60 days). Most acute infections resolve spontaneously, with symptoms disappearing within 4-6 weeks. However, acute HEV infection can cause acute liver failure, most commonly in pregnant females in the developing world as described above. Whereas acute HEV infection can cause severe acute liver injury in the Western world, it rarely causes acute liver failure. Genotype 1 and 2 infections have also been implicated in the development of acute on chronic liver failure/decompensated liver disease. In countries where HEV is endemic, the number of cases of acute on chronic liver failure secondary to HEV is variable (ranging from 4% to 75%) with a median short term mortality rate of 34% (range 0% -100%) 59 . One study from
India reported a 70% 12-month mortality rate in patients with HEV infection superimposed upon chronic liver disease and interestingly, HEV infection was associated with a higher mortality rate than decompensation due to any other cause 60 .
GENOTYPE 3 AND 4 INFECTION
Epidemiology - Figure estimates of seroprevalence ranged from 0.6% to 52.5%, with rates increasing with age but unrelated to gender 61 . In the United States, seroprevalence for anti-HEV is around 6% 62 , in the United Kingdom 3-16% 63 and in some regions of France up to 52% 64 . In England, the number of confirmed . However, a study from South-East England suggested that there are 80,000-100,000 infections per year in England, the majority of which are asymptomatic 66 .
Autochthonous (locally acquired) HEV infection is not a benign condition, with mortality rates up to 27% reported in patients with underlying chronic liver disease 67 .
Interesting geographical variations in genotype 3 HEV infection have been observed in France where there is considerable variation in seroprevalence by region from 8-86%
68
; very high seroprevalence occurs in the southwest, southeast and northeast of the country 67, 68, 69 . The reason for this interesting observation is unclear, but contaminated foodstuffs in the food chain are likely to explain these geographical differences in part. There appears to be no correlation with potential transmission routes (e.g. location of pig farms). Although Scotland is a relatively low seroprevalence region, seroprevalence rates are also variable 70 . This geographical variation in HEV infection is worthy of further consideration and investigation. As in France the main pig-rearing/farming region is located in the North East of Scotland, in contrast to the area of peak HEV seroprevalence 70, 71 . In a study of patients with decompensated chronic liver disease from the United Kingdom and France, HEV was significantly more common in the French cohort compared with the United Kingdom cohort (7.9% versus 1.2% respectively; p = 0.003) 67 . Potential explanations for this include the quantum of circulating HEV in these respective regions, and the exposure to contaminated foodstuffs.
Many countries have undertaken epidemiological studies of HEV seroprevalence in their respective blood donor populations (Table 2) 72-81 . Most countries report increasing incidence of HEV infection due to increased awareness of HEV, increased testing for the virus and a true increase in the numbers of new infections. Data from the Netherlands and Scotland suggests that this increase in incidence appears to be in younger patients, in contrast with previous observations that autochthonous HEV infection predominantly affects older (>60 years) males 70, 82 . 88 . In a study of blood donors exposed to HEV infection in Southern France, foodstuffs associated with positive antibodies against HEV on multivariate analysis were uncooked pork liver sausages, offal and mussels 74 . To support this, HEV has been found to be highly prevalent amongst global pig populations. For example, in Germany, 33% of wild boar and 50% of domestic pigs are seropositive for anti-HEV IgG 89, 90 . HEV infection has been identified in more than 80% of some pig herds in the United States, Canada and in the United Kingdom (England) 91, 92 , although
Scottish herds have a lower seroprevalence of around 62% 93 . In a more recent report on English and
Northern Irish pigs, 93% of slaughter age animals were seropositive 91 .
In the West of Scotland, 92% of tested wild caught mussels were PCR positive for HEV and consumption of undercooked/raw shellfish is another viable route of transmission 46 . Likewise, numerous studies have indicated HEV contamination of soft fruits, likely via exposure to contaminated water. In Quebec, Canada swine HEV was detected in strawberries (1.6% of samples tested) 94 . A separate study of the European berry fruit supply chain identified HEV in 2.6% of berries (raspberries) at point of sale 95 . A more recent study identified HEV in 5% of irrigation water samples from leafy green vegetable production chains 96 .
In view of the seroprevalence in animal populations described above, it seems logical that HEV can be transmitted to humans via the consumption of contaminated foodstuffs. Several studies have . Therefore, HEV-contaminated cows milk is another potential zoonotic source; gavage of infected milk to rhesus macaques resulted in active HEV in infection as confirmed by HEV RNA in blood and faeces. However, in milk samples collected from dairy farms (i.e. not mixed farms) in Germany, no HEV RNA was detected 99 . The exact contribution of zoonotic HEV infection via dairy milk, and the potential contamination via mixed farming remains to be established. 
Transmission: via blood products

Clinical Features
Immunocompetent individuals clear HEV promptly, usually within a few weeks. In these patients, HEV infection usually runs a mild course and is often asymptomatic. However, in the immunocompromised, HEV infection is often more difficult to clear, and about 60% of these patients go on to develop chronic HEV infection 6, 7 . Chronic HEV infection may lead to complications such as liver cirrhosis.
Clinical Features of Genotype 3 HEV infection
In 2008 it was established that genotype 3 HEV infection may progress to chronic infection in patients who are immunocompromised (e.g. patients with HIV, leukaemia, high dose steroid therapy) and solid organ transplant recipients 6, 107, 108 . . In a retrospective study analysing stored plasma from 2,919 HIVinfected patients, 3 female patients were identified to have had HEV infection: 2 patients had acute HEV infection and 1 patient had chronic HEV infection for > 4 years (all infections genotype 3a) 112 . In addition to chronic HEV infection, reactivation of resolved infection has also been reported. One patient who had undergone stem cell transplant for leukaemia and was therefore immunosuppressed. A UK/French study also looked at the role of HEV infection in patients with decompensated chronic liver disease 67 . Acute HEV infection (genotype 3) was identified in a minority (3.2%) of patients with decompensated chronic liver disease, and there were no differences in mortality between patients with and without HEV infection. It is likely that HEV genotype 3 infection in patients with chronic liver disease confers an adverse prognosis (similar to that of other insults causing decompensation), but this effect is less than that seen with HEV genotype 1 infection as seen in a cohort of Indian patients 60 . The role of the genotype of HEV in acute on chronic liver failure/decompensated chronic liver disease and its effect on patient outcome is therefore less certain, and requires further investigation.
Versluis described a patient who had initially cleared HEV infection
EXTRAHEPATIC MANIFESTATIONS OF HEV
HEV infection may also present with extrahepatic manifestations. In vitro data has identified that HEV can replicate in non-liver cells including human intestine There is currently no consensus across laboratories for HEV testing, and the sensitivity and specificity of HEV assays vary widely. This may at least in part account for the differences in reported rates of anti-HEV antibody in various populations. For example, within one country (UK), the prevalence of anti-HEV antibody in the blood donor population was 3.6% as detected by one assay, compared with 16.2% with the use of an alternative 63 . In the recent meta-analysis of HEV seroprevalence in Europe by Hartl, seroprevalence again varied depending upon the assay used, with the Wantai assay reporting significantly higher seroprevalence rates across all cohorts tested 61 . ; the preexisting anti-HEV IgG concentration was <7 WU mL -1 , and one patient had a serologic profile indicating 4 consecutive reinfections in intervals of 1.2-3.4 years.
TREATMENT OF HEV INFECTION
Liver transplantation for fulminant hepatitis
It is rare for patients with HEV induced acute liver failure to require emergency liver transplantation.
The 
Medical Therapy
Following the identification of chronic HEV infection, there were case reports of successful viral clearance following ribavirin and/or pegylated interferon treatment. Both ribavirin and pegylated interferon inhibit HEV replication in vitro. However, pegylated interferon is contraindicated in kidney transplant recipients due to an appreciable risk of acute rejection and ribavirin has subsequently become the first line medical treatment for both acute (if required) and chronic HEV infection (Table   3) 111 monotherapy is the treatment of choice for the majority of patients (Table 3) 111, [130] [131] [132] [133] [134] [135] . 
PREVENTION OF HEV INFECTION
GENOTYPE 1 and 2 INFECTION
HEV is becoming a real global public health problem, and a focus on prevention of infection must be considered. Globally, basic sanitation must remain the first line of defence against HEV infection.
However, it is recognised that during outbreaks, basic sanitation and simple health interventions do not adequately prevent additional infections. Therefore, a vaccine against HEV is highly desirable, particularly for residents living in highly endemic areas and for those at high risk of developing complications e.g. the immunosuppressed. As all HEV genotypes belong to the same serotype, it is thought that one HEV vaccine should provide protection against all HEV genotypes. Due to difficulties in culturing HEV, it has not been feasible to produce enough virus for vaccine production for either live attenuated or inactivated vaccine against this virus 
GENOTYPE 3 and 4 INFECTION
In the Western world, as transmission is predominantly via undercooked foodstuffs there must be education on adequate cooking to minimise risk of transmission via the food chain: for example, the risk of HEV transmission via foodstuffs is significantly reduced by cooking meat for 1 minute at Table 4 152 .
NEW APPROACHES TO TREATMENT, FUTURE WORK AND RECOMMENDATIONS
Firstly, standardisation of diagnostic assays is key to ensure as many cases of HEV infection are Table 1 . Characteristics of HEV infection according to genotype. Table 2 . HEV seroprevalence in screened blood donor populations Table 3 . Treatment of chronic HEV infection with ribavirin in immunosuppressed patients Table 4 . Recommendations on the use of HEV-screened blood components Table 5 . Clinicians guide to testing for and treatment of hepatitis E 
